AYTU BIOPHARMA, INC Form DEF 14A: Definitive proxy statement
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2025-10-24: Form DEF 14A; Period of report 2025-12-10; Description FORM DEF 14A; Document aytu20250915_def14a.htm.
- 2025-03-28: Form DEF 14A; Period of report 2025-05-21; Description FORM DEF 14A; Document aytu20250213_def14a.htm.
- 2024-05-10: Form DEF 14A; Period of report 2024-06-26; Description FORM DEF 14A; Document aytu20240409_def14a.htm.
- 2023-04-07: Form DEF 14A; Period of report 2023-05-18; Description DEF 14A; Document tmb-20230518xdef14a.htm.
| Filed | Form | Period of report | Description | Document |
|---|---|---|---|---|
| 2025-10-24 | DEF 14A | 2025-12-10 | FORM DEF 14A | aytu20250915_def14a.htm |
| 2025-03-28 | DEF 14A | 2025-05-21 | FORM DEF 14A | aytu20250213_def14a.htm |
| 2024-05-10 | DEF 14A | 2024-06-26 | FORM DEF 14A | aytu20240409_def14a.htm |
| 2023-04-07 | DEF 14A | 2023-05-18 | DEF 14A | tmb-20230518xdef14a.htm |
| 2022-08-25 | DEF 14A | 2022-10-05 | DEF 14A | tmb-20221005xdef14a.htm |
| 2022-04-07 | DEF 14A | 2022-05-18 | DEF 14A | tm2210624-1_def14a.htm |
| 2021-04-19 | DEF 14A | 2021-04-16 | FORM DEF 14A | aytu20210416_def14a.htm |
| 2020-03-04 | DEF 14A | 2020-03-31 | DEFINITIVE PROXY STATEMENT | ea119296-def14a_aytubio.htm |
| 2019-12-23 | DEF 14A | 2020-01-24 | DEFINITIVE PROXY STATEMENT | def14a1219_aytubioscience.htm |
| 2019-02-25 | DEF 14A | 2019-02-25 | PRIMARY DOCUMENT | aytu_14a.htm |
| 2018-05-09 | DEF 14A | 2018-06-27 | DEFINITIVE PROXY STATEMENT | def14a0518_aytubioscience.htm |
| 2017-06-16 | DEF 14A | 2017-07-26 | DEF 14A | v468507_def14a.htm |
| 2016-10-05 | DEF 14A | 2016-11-15 | DEF 14A | v449779_def14a.htm |
| 2016-04-13 | DEF 14A | 2016-05-24 | DEF 14A | v436429_def14a.htm |
| 2015-05-12 | DEF 14A | 2015-06-01 | DEF 14A | d910772ddef14a.htm |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |